|
SH3BGRL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.90640000031462E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.48939999994524E-06 |
| Normal-vs-Stage2 |
3.669900E-02 |
| Normal-vs-Stage3 |
2.78729999969585E-07 |
| Normal-vs-Stage4 |
2.90869550667594E-11 |
| Stage1-vs-Stage2 |
4.121800E-01 |
| Stage1-vs-Stage3 |
1.133960E-01 |
| Stage1-vs-Stage4 |
9.72780000000339E-05 |
| Stage2-vs-Stage3 |
8.908000E-02 |
| Stage2-vs-Stage4 |
1.815570E-03 |
| Stage3-vs-Stage4 |
3.065600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.30629999939691E-08 |
| Normal-vs-AfricanAmerican |
2.240000E-01 |
| Normal-vs-Asian |
2.15749999999959E-05 |
| Caucasian-vs-AfricanAmerican |
3.562000E-01 |
| Caucasian-vs-Asian |
6.460600E-01 |
| AfricanAmerican-vs-Asian |
2.811200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.60050000003387E-06 |
| Normal-vs-Female |
2.16819999954154E-07 |
| Male-vs-Female |
8.872000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.03230000000088E-05 |
| Normal-vs-Age(41-60Yrs) |
2.45119999964238E-07 |
| Normal-vs-Age(61-80Yrs) |
2.0495999999981E-05 |
| Normal-vs-Age(81-100Yrs) |
4.188000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.030000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.550800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.869400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.196000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.527400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.502600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.390100E-02 |
| Classical-VS-Follicular |
1.384240E-01 |
| Classical-VS-Other |
7.354200E-01 |
| Classical-VS-Normal |
1.15339999995356E-06 |
| Tall-VS-Follicular |
2.740000E-02 |
| Tall-VS-Other |
2.411200E-01 |
| Tall-VS-Normal |
1.08700000001072E-06 |
| Follicular-VS-Other |
8.844200E-01 |
| Follicular-VS-Normal |
1.066340E-02 |
| Other-VS-Normal |
1.275390E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.9968799999992E-05 |
| Normal-vs-N1 |
1.6189000140443E-09 |
| N0-vs-N1 |
4.118400E-03 |
|
|
